Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 14/20 | 0.77 |
| ▸ | ACE | P12821 | 2/20 | 0.67 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16566050 | 0.93 | ECE1 (0.74) | ECE1ACEMMP1MMP3MMP9 | |
| SCHEMBL8905663 | 0.93 | ECE1 (0.74) | ECE1ACEMMP1MMP3MMP9 | |
| SCHEMBL24122594 | 0.89 | ECE1 (0.69) | ECE1ACEMMP9MMP8 | |
| SCHEMBL30493767 | 0.89 | ECE1 (0.69) | ECE1ACEMMP9MMP8 | |
| SCHEMBL5558360 | 0.89 | ECE1 (0.69) | ECE1ACEHPGDS | |
| SCHEMBL30291268 | 0.89 | ECE1 (0.69) | ECE1ACEHPGDS | |
| SCHEMBL18909648 | 0.88 | ECE1 (0.69) | ECE1ACEMMP9MMP8 | |
| SCHEMBL13784699 | 0.88 | ECE1 (0.69) | ECE1ACEMMP1MMP3MMP9 | |
| SCHEMBL23380923 | 0.88 | ECE1 (0.69) | ECE1ACEMMP1MMP3MMP9 | |
| Acetyltryptophanamide SCHEMBL22850012 | 0.88 | ECE1 (0.68) | ECE1ACEMMP9MMP8HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169676-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | WASHINGTON UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | WASHINGTON UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | HDGF, MMP7, HGF | ECE1 373/4885ACE 479/4885MMP1 119/4885 |
| US-20220169676-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | HDGF, MMP7, HGF | ECE1 373/4885ACE 479/4885MMP1 119/4885 |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | ECE1 657/4885ACE 1059/4885MMP1 3376/4885 |
| US-20180066015-A1 | INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES | HDGF, MMP7, HGF | ECE1 373/4885ACE 479/4885MMP1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.